IC
PPH icon

Inscription Capital’s VanEck Pharmaceutical ETF PPH Stock Holding History

Inscription Capital’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,400
Closed -$218K – 545
2025
Q1 		$218K Buy
+2,400
New +$216K 0.04% 310
2024
Q3 		$228K Hold
2,400
– – 0.03% 335
2024
Q2 		$220K Hold
2,400
– – 0.04% 314
2024
Q1 		$218K Buy
+2,400
New +$210K 0.04% 310

Other funds holding PPH

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
AT
Avalon Trust Santa Fe, New Mexico $1.45B AUM 35.31% 1-Year Est. Return
JSAM
J. Safra Asset Management New York $1.86B AUM 22.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AWC
Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

Inscription Capital's PPH Position: Q2 2025 in Review

Inscription Capital sold out of VanEck Pharmaceutical ETF (PPH) in Q2 2025, closing a stake of 2,400 shares — an estimated $218K sold.

Inscription Capital first reported a position in PPH in Q1 2024 and held it in 4 quarters. The position peaked at $228K in Q3 2024. 129 funds tracked by Wall St. Rank hold PPH as of Q2 2025.

  • Inscription Capital reported no remaining VanEck Pharmaceutical ETF position as of Q2 2025 after selling out during the quarter.
  • Inscription Capital sold 2,400 VanEck Pharmaceutical ETF shares in Q2 2025, an estimated $218K.
  • Inscription Capital first reported a position in VanEck Pharmaceutical ETF in Q1 2024 and held it in 4 quarters.
  • Inscription Capital's VanEck Pharmaceutical ETF position peaked at $228K in Q3 2024.
  • 129 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2025.

Based on Inscription Capital's 13F filing for Q2 2025, filed 12 Aug 2025.